Vitrolife AB
STO:VITR

Watchlist Manager
Vitrolife AB Logo
Vitrolife AB
STO:VITR
Watchlist
Price: 131.8 SEK -1.86%
Market Cap: 17.9B SEK

Operating Margin
Vitrolife AB

18.7%
Current
-8%
Average
-4.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.7%
=
Operating Profit
657m
/
Revenue
3.5B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
SE
Vitrolife AB
STO:VITR
17.8B SEK
19%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
395.3B USD
33%
US
Amgen Inc
NASDAQ:AMGN
175.8B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
147.5B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.6B USD
28%
AU
CSL Ltd
ASX:CSL
84B AUD
26%
NL
argenx SE
XBRU:ARGX
45.1B EUR
22%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
51.6B USD
8%
No Stocks Found

Vitrolife AB
Glance View

Market Cap
17.8B SEK
Industry
Biotechnology

Vitrolife AB is a Swedish company that has carved out a significant niche within the biotechnology sector, particularly within reproductive health. Founded in 1994, Vitrolife focuses on the development, production, and commercialization of products designed to optimize fertility treatments. The company’s offerings include a wide range of medical devices and culture media critical for in vitro fertilization (IVF) procedures. These products are used by fertility clinics across the globe, enhancing every stage of assisted reproduction — from egg retrieval and sperm preparation to embryo transfer. This comprehensive approach not only amplifies treatment outcomes but also strengthens Vitrolife's position as a pivotal player in a market where scientific advancement and patient care converge. The company’s business model thrives on a robust combination of research-driven innovation and strategic acquisitions. By continuously refining its product lines and leveraging strategic partnerships with clinics and research institutes, Vitrolife ensures that it remains at the cutting edge of the rapidly evolving fertility landscape. Revenue streams flow in through the sales of these critical fertility products, supported by a well-established distribution network that bridges its Swedish roots with a global customer base. With a commitment to quality and efficacy, Vitrolife makes money by delivering solutions that enhance the success rates of fertility treatments, making the dream of parenthood possible for many around the world.

VITR Intrinsic Value
131.68 SEK
Fairly Valued
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
18.7%
=
Operating Profit
657m
/
Revenue
3.5B
What is the Operating Margin of Vitrolife AB?

Based on Vitrolife AB's most recent financial statements, the company has Operating Margin of 18.7%.

Back to Top